



## Andrea Rubbert-Roth

Rheumatologie · Dept. I

### Kontakt

Andrea Rubbert-Roth

T +41 71 494 1439

### Bereiche

Rheumatologie

## Publikationen (53)

Ciurea A, Götschi A, Bräm R, Bürki K, Exer P, Andor M, Nissen M, Möller B, Hügler T, Rubbert-Roth A, Kyburz D, Distler O, Scherer A, Micheroli R. Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry. *RMD Open* 2023; 9

Rubbert-Roth A, Kakehasi A, Takeuchi T, Schmalzing M, Palac H, Coombs D, Liu J, Anyanwu S, Lippe R, Curtis J. Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis. *Rheumatol Ther* 2023

Spiera R, Unizony S, Warrington K, Sloane J, Giannelou A, Nivens M, Akinlade B, Wong W, Bhore R, Lin Y, Buttgerit F, Devauchelle-Pensec V, Rubbert-Roth A, Yancopoulos G, Marrache F, Patel N, Dasgupta B, SAPHYR Investigators. Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper. *N Engl J Med* 2023; 389:1263-1272.

Finckh A, Ciurea A, Raptis C, Rubbert-Roth A. Susceptibility to COVID-19 and Immunologic Response to Vaccination in Patients With Immune-Mediated Inflammatory Diseases. *J Infect Dis* 2023; 228:S13-S23.

Micheroli R, Kissling S, Bürki K, Möller B, Finckh A, Nissen M, Exer P, Bräm R, Kyburz D, Rubbert-Roth A, Andor M, Baraliakos X, de Hooge M, Distler O, Scherer A, Ciurea A. Anaemia is associated with higher disease activity in axial spondyloarthritis but is not an independent predictor of spinal radiographic progression: data from the Swiss Clinical Quality Management Registry. *Clin Rheumatol* 2023; 42:2377-2385.

Rubbert-Roth A. Methotrexate in rheumatoid arthritis-another brick in the wall. *Lancet Rheumatol* 2023; 5:e173-e175.

Taylor P, Chen Y, Pope J, Weinblatt M, Mysler E, Rubbert-Roth A, Jia B, Sun L, Liu Y, Holzkämper T, Tanaka Y. Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies. *Rheumatol Ther* 2023; 10:463-476.

Amstad A, Papagiannoulis E, Scherer A, Rubbert-Roth A, Finckh A, Mueller R, Dudler J, Möller B, Villiger P, Schulz M, Kyburz D. Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy. *Rheumatology (Oxford)* 2022; 62:89-97.

Koehm M, Foldenauer A, Rossmann T, Alten R, Aringer M, Backhaus M, Burmester G, Feist E, Kellner H, Krueger K, Müller-Ladner U, Rubbert-Roth A, Tony H, Wassenberg S, Burkhardt H, Behrens F. Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA). *J Clin Med* 2022; 11

Smolen J, Landewé R, Bergstra S, Kerschbaumer A, Sepriano A, Aletaha D, Caporali R, Edwards C, Hyrich K, Pope J, de Souza S, Stamm T, Takeuchi T, Verschueren P, Winthrop K, Balsa A, Bathon J, Buch M, Burmester G, Buttgerit F, Cardiel M, Chatzidionysiou K, Codreanu C, Cutolo M, den Broeder A, El Aoufy K, Finckh A, Fonseca J, Gottenberg J, Haavardsholm E, Iagnocco A, Lauper K, Li Z, McInnes I, Mysler E, Nash P, Poór G, Ristic G, Rivellese F, Rubbert-Roth A, Schulze-Koops H, Stoilov N, Strangfeld A, van der Helm-van Mil A, van Duuren E, Vliet Vlieland T, Westhovens R, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. *Ann Rheum Dis* 2022

Raptis C, Berger C, Ciurea A, Andrey D, Polysopoulos C, Lescuyer P, Maletic T, Riek M, Scherer A, von Loga I, Safford J, Lauper K, Möller B, Vuilleumier N, Finckh A, Rubbert-Roth A. Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases. *Front Immunol* 2022; 13:1016927.

Rubbert-Roth A, Furst D, Fiore S, Praetgaard A, Bykerk V, Bingham C, Charles-Schoeman C, Burmester G. Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab. *Arthritis Res Ther* 2022; 24:207.

Rubbert-Roth A. [ORAL SURVEILLANCE: what has changed in the risk assessment of JAK inhibitors?]. *Z Rheumatol* 2022; 81:780-781.

Aletaha D, Kerschbaumer A, Kastrati K, Dejaco C, Dougados M, McInnes I, Sattar N, Stamm T, Takeuchi T, Trauner M, van der Heijde D, Voshaar M, Winthrop K, Ravelli A, Betteridge N, Burmester G, Bijlsma J, Bykerk V, Caporali R, Choy E, Codreanu C, Combe B, Crow M, de Wit M, Emery P, Fleischmann R, Gabay C, Hetland M, Hyrich K, Iagnocco A, Isaacs J, Kremer J, Mariette X, Merkel P, Mysler E, Nash P, Nurmohamed M, Pavelka K, Poór G, Rubbert-Roth A, Schulze-Koops H, Strangfeld A, Tanaka Y, Smolen J. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. *Ann Rheum Dis* 2022

Schmiedeberg K, Rassouli F, von Kempis J, Rubbert-Roth A. Anti-interleukin-23 directed therapy and the recurrence of severe allergic asthma. *Rheumatology (Oxford)* 2022

Schmiedeberg K, Abela I, Pikor N, Vuilleumier N, Schwarzmüller M, Epp S, Pagano S, Grabherr S, Patterson A, Nussberger M, Trkolia A, Ludewig B, von Kempis J, Rubbert-Roth A. Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA. *RMD Open* 2022; 8

Burmester G, Liu J, Mccaskill R, Lertratanakul A, Lippe R, Lesser E, Rubbert-Roth A, Salvarani C, Azevedo V, Goupille P, Nash P, Blanco R, Winthrop K, Ruderman E. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials. *Rheumatol Ther* 2021

Rubbert-Roth A, Vuilleumier N, Ludewig B, Schmiedeberg K, Rottländer Y, Pirker I, von Kempis J (2021). Anti-S1 Antibodies After Vaccination with Anti SARS-CoV-2 mRNA Vaccines in Patients with Rheumatoid Arthritis Differ in Magnitude and Kinetics from Healthy Controls: Results from a Prospective, Observational Controlled Study.

Rehberg M, Choy E, Rubbert-Roth A, Castañeda S, Schwarting A, Gottenberg J, Curtis J, Iglesias-Rodríguez M, van Hoogstraten H, Praetgaard A, Giegerich C, MOBILITY, MONARCH, TARGET, and ASCERTAIN investigators. Correction to: Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data. *Rheumatol Ther* 2021; 8:1921-1922.

Vuilleumier N, Pagano S, Ludewig B, Schmiedeberg K, Haller C, von Kempis J, Rubbert-Roth A. Anti-SARS-CoV-2 mRNA vaccines as inducers of humoral response against apolipoprotein A-1?. *Eur J Clin Invest* 2021; 52:e13713.

Joos L, Vetterli F, Jaeger T, Cozzio A, von Kempis J, Rubbert-Roth A. Treatment of refractory subacute cutaneous lupus erythematosus with baricitinib. *Clin Exp Dermatol* 2021

Schmiedeberg K, Vuilleumier N, Pagano S, Albrich W, Ludewig B, von Kempis J, Rubbert-Roth A. Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses. *Lancet Rheumatol* 2021; 4:e11-e13.

Haller C, Cozzio A, von Kempis J, Rubbert-Roth A. Successful Treatment of Rituximab-Associated Palmoplantar Pustulosis With Apremilast in a Patient With Seropositive Rheumatoid Arthritis. *J Clin Rheumatol* 2021; 27:e289-e290.

Rubbert-Roth A, Schmiedeberg K, von Kempis J. Pausing drugs and spacing vaccines: an open question - Authors' reply. *Lancet Rheumatol* 2021; 3:e683-e684.

Rehberg M, Choy E, Rubbert-Roth A, Castañeda S, Schwarting A, Gottenberg J, Curtis J, Iglesias-Rodríguez M, van Hoogstraten H, Praestgaard A, Giegerich C, MOBILITY, MONARCH, TARGET, and ASCERTAIN investigators. Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data. *Rheumatol Ther* 2021; 8:1661-1675.

Gilbert B, Moeller B, Kyburz D, Rubbert-Roth A, Courvoisier D, Studer O, Trunk E, Lauper K, Mongin D, Lamacchia C, Finckh A. Cohort profile: SCREEN-RA: design, methods and perspectives of a Swiss cohort study of first-degree relatives of patients with rheumatoid arthritis. *BMJ Open* 2021; 11:e048409.

Rubbert-Roth A, Vuilleumier N, Ludewig B, Schmiedeberg K, Haller C, von Kempis J. Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis. *Lancet Rheumatol* 2021; 3:e470-e472.

Rubbert-Roth A, Xavier R. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. Reply. *N Engl J Med* 2021; 384:83-84.

Behrens F, Wassenberg S, Tony H, Rubbert-Roth A, Müller-Ladner U, Lehn A, Krueger K, Kellner H, Herrmann E, Feist E, Burmester G, Backhaus M, Aringer M, Alten R, Rossmann T, Koehm M, Burkhardt H. Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study). *Rheumatology (Oxford)* 2021; 60:5318-5328.

Manoil D, Courvoisier D, Gilbert B, Möller B, Walker U, Muehlenen I, Rubbert-Roth A, Finckh A, Bostanci N. Associations between serum antibodies to periodontal pathogens and preclinical phases of rheumatoid arthritis. *Rheumatology (Oxford)* 2021; 60:4755-4764.

Rubbert-Roth A, Aletaha D, Devenport J, Sidiropoulos P, Luder Y, Edwardes M, Jacobs J. Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis. *Rheumatology (Oxford)* 2021; 60:682-691.

Burmester G, Taylor P, Szekanecz Z, Stamm T, Rubbert-Roth A, Ramiro S, Østergaard M, Montecucco C, Iagnocco A, Gabay C, Ferreira R, Fautrel B, Durez P, Combe B, Calvo Alén J, Betteridge N, Álvaro-Gracia J, van de Laar M. Evolving the comprehensive management of rheumatoid arthritis: identification of unmet needs and development of practical and educational tools. *Clin Exp Rheumatol* 2020; 38:1056-1067.

Ciurea A, Scherer A, Distler O, Kyburz D, Dan D, Müller A, Bräm R, Andor M, Rubbert-Roth A, Möller B, Micheroli R, von Loga I, Bürki K, Papagiannoulis E, Finckh A. Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort. *Ann Rheum Dis* 2020; 80:238-241.

Rubbert-Roth A, Neumann T, Glaser-Gallion F. Diagnostische Herausforderungen bei einer Kleingefäßvaskulitis. *Swiss Med Forum* 2020; 2020/3134:466-468.

Padberg Sgier B, Veraguth K, Median D, Niklaus M, Rubbert-Roth A, Glaser-Gallion F, Neumann T. Diagnostische Herausforderungen bei einem 54-jährigen Mann mit einer Kleingefäßvaskulitis. *Swiss Med Forum* 2020; 20:466-468.

Kedor C, Specker C, Seipelt E, Schulze-Koops H, Rubbert-Roth A, Kekow J, Henes J, Blank N, Behrens F, Weiß A, Zernicke J, Listing J, Feist E. Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. *Ann Rheum Dis* 2020; 79:1090-1097.

Pirker I, Rubbert-Roth A, von Kempis J, Fehr M, Neumann T. Tocilizumab in a patient with newly diagnosed rheumatoid arthritis secondary to checkpoint inhibitor therapy. *Clin Exp Rheumatol* 2020

van der Heijde D, Mariette X, Li Z, Koloumas M, Huizinga T, Hetland M, Gottenberg J, Gossec L, Finckh A, Emery P, Müller-Ladner U, Mysler E, da Silva J, Westhovens R, Voshaar M, Takeuchi T, Strangfeld A, Saag K, Ruysen-Witrand A, Rubbert-Roth A, Pope J, Poór G, van Eijk-Hustings Y, Edwards C, Cutolo M, de Wit M, van Vollenhoven R, Sepriano A, McInnes I, Kerschbaumer A, Dougados M, Burmester G, Bijlsma J, Landewé R, Aletaha D, Aringer M, Askling J, Codreanu C, De Cock D, Cardiel M, Caporali R, Buttgereit F, Buch M, den Broeder A, Boers M, Balsa A, Smolen J. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis* 2020; 79:685-699.

Rubbert-Roth A, Enejosa J, Pangan A, Haraoui B, Rischmueller M, Khan N, Zhang Y, Martin N, Xavier R. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. *N Engl J Med* 2020; 383:1511-1521.

Poddubnyy D, Amital H, Rubbert-Roth A. Should we combine biologics with methotrexate in axial spondyloarthritis?. *Autoimmun Rev* 2019; 18:102402.

Rubbert-Roth A, Szabó M, Kedves M, Nagy G, Atzeni F, Sarzi-Puttini P. Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents. *Autoimmun Rev* 2019; 18:102398.

Burmester G, Boklage S, St John G, Thangavelu K, Gervitz L, Pena-Rossi C, Gómez-Centeno A, Raskina T, Amital H, Rubbert-Roth A, Strand V, Genovese M. Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension. *RMD Open* 2019; 5:e001017.

Mueller R, Schulze-Koops H, Rubbert-Roth A, Hasler P, Souza A, Durmisi M, Mattow F, Popp F, Hasler C, von Kempis J. Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts. *J Clin Med* 2019; 8

Dörner T, Peters M, Schwenke H, Rubbert-Roth A, Krüger K, Kurthen R, Kellner H, Kästner P, Engel A, Schmalzing M, Iking-Konert C, Burmester G, Schulze-Koops H, Tony H. Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRA). *Clin Exp Rheumatol* 2019; 37:937-945.

Krause A, Rubbert-Roth A. [Pulmonary involvement in rheumatoid arthritis]. *Z Rheumatol* 2019; 78:228-235.

Fiehn C, Kuipers J, Lorenz H, Müller-Ladner U, Nothacker M, Nüsslein H, Rubbert-Roth A, Schneider M, Schulze-Koops H, Seitz S, Sitter H, Specker C, Tony H, Wassenberg S, Wollenhaupt J, Krause A, Kellner H, Gromnica-Ihle E, Holle J, Iking-Konert C, Leipe J, Weseloh C, Frerix M, Alten R, Behrens F, Baerwald C, Braun J, Burkhardt H, Burmester G, Detert J, Gaubitz M, Gause A, Krüger K. [S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs]. *Z Rheumatol* 2018; 77:35-53.

Genovese M, Meerwein S, Mohamed M, Zhou Y, Zhang Y, Rubbert-Roth A, Hall S, Combe B, Fleischmann R, Pangan A. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. *Lancet* 2018; 391:2513-2524.

Rubbert-Roth A, Furst D, Nebesky J, Jin A, Berber E. A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases. *Rheumatol Ther* 2018; 5:21-42.

Alten R, Burkhardt H, Feist E, Krüger K, Rech J, Rubbert-Roth A, Voll R, Elbez Y, Rauch C. Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting. *Arthritis Res Ther* 2018; 20:1.

Rubbert-Roth A, Atzeni F, Masala I, Caporali R, Montecucco C, Sarzi-Puttini P. TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same?. *Autoimmun Rev* 2018; 17:24-28.

Rubbert-Roth A, Atzeni F, Masala I, Caporali R, Montecucco C, Sarzi-Puttini P. TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same?. *Autoimmun Rev* 2017; 17:24-28.

Michels G, Radtke A, Rubbert-Roth A, Pfister R, Quaas A. [51-year-old man with acute coronary syndrome and bipulmonary infiltrates]. *Dtsch Med Wochenschr* 2017; 142:1545.

Rubbert-Roth A, Jacobs J, Bijlsma J, Welsing P. A disconnect between disease activity and functional ability already in patients with early rheumatoid arthritis, depending on large joint involvement. *Ann Rheum Dis* 2017; 77:1085-1086.

## Projekte (31)

**Boehringer Ingelheim BI1366-0031\_456906\_SSc**

*Klinische Forschung - 22.05.2023 - 22.05.2026*

*Laufend*

**Acceleron\_A1334-02**

*Klinische Forschung - 14.04.2023 - 14.04.2026*

*Laufend*

**Novartis\_CAIN457C22301**

*Klinische Forschung - 10.03.2023 - 10.03.2026*

*Laufend*

**Novartis\_CLNA043A12203**

*Klinische Forschung - 30.12.2022 - 31.12.2025*

*Laufend*

**Horizon\_HZNP-HZN-825-301**

*Klinische Forschung - 30.11.2022 - 31.12.2025*

*Laufend*

**Athena-SSc-ILD-Study**

*Klinische Forschung - 23.08.2022 - 23.08.2024*

*Automatisch geschlossen*

**BMS\_IM101-863**

*Klinische Forschung - 24.01.2022 - 17.01.2025*

*Abgeschlossen*

**Novartis CAIN457R12301**

*Klinische Forschung - 01.01.2022 - 01.01.2025*

*Laufend*

**AbbVie UPSTAND P20-410 SLEESPA**

*Klinische Forschung - 10.12.2021 - 10.12.2024*

*Laufend*

**Amgen 20200234**

*Klinische Forschung - 08.09.2021 - 06.04.2023*

*Abgebrochen*

**RECOVER: Rheumatoid Covid-19 Vaccine Immune Response**

*Klinische Forschung - 01.02.2021 - 31.12.2022*

*Abgeschlossen*

**IFX-1-P2.5**

*Klinische Forschung - 01.11.2020 - 01.11.2021*

*Abgeschlossen*

**I4V-MC-JAIM**

*Klinische Forschung - 12.08.2020 - 12.08.2022*

*Abgeschlossen*

**Abbvie UPHOLD P20-095 SLEERA**

*Klinische Forschung - 01.08.2020 - 31.10.2023*

*Automatisch geschlossen*

**CAIN457Q12301**

*Klinische Forschung - 13.07.2020 - 12.07.2023*

*Automatisch geschlossen*

**IgPro20\_3007: RECLAIM**

*Klinische Forschung - 05.02.2020 - 30.12.2025*

*Laufend*

**RA Bridge**

*Klinische Forschung - 03.10.2019 - 30.07.2023*

*Automatisch geschlossen*

**Amgen CC-10004-PsA-014 MOSAIK**

*Klinische Forschung - 31.07.2019 - 31.08.2021*

*Abgeschlossen*

**Sanofi PMR EFC15160**

*Klinische Forschung - 04.07.2019 - 08.07.2021*

*Automatisch geschlossen*



**Sanofi GCA EFC15068**

*Klinische Forschung - 04.07.2019 - 08.07.2020*

*Abgebrochen*

**Abbvie M16-852 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and**

*Klinische Forschung - 02.04.2019 - 31.12.2024*

*Laufend*

**Lilly JAHZ A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib**

*Klinische Forschung - 28.02.2019 - 28.02.2022*

*Abgeschlossen*

**CORBUS: Lenabasum bei diffuser systemischer Sklerose**

*Klinische Forschung - 25.09.2018 - 27.09.2021*

*Abgebrochen*

**Abbvie M15-925: A Phase 3, Randomized, Active-Controlled,**

*Klinische Forschung - 15.08.2018 - 16.08.2024*

*Abgeschlossen*

**Skippain**

*Klinische Forschung - 29.01.2018 - 29.06.2019*

*Abgeschlossen*

**Lilly RHCF SPIRIT**

*Klinische Forschung - 16.10.2017 - 24.10.2021*

*Abgeschlossen*

**Abbvie M15-572 Phase 3 PsA mit inadäquater Response auf bDMARD**

*Klinische Forschung - 02.10.2017 - 03.10.2024*

*Automatisch geschlossen*

**CCX\_Chemocentryx CL010 CCX168 (Avacopan)**

*Klinische Forschung - 15.05.2017 - 31.05.2021*

*Abgeschlossen*

**Maximise**

*Klinische Forschung - 05.12.2016 - 13.09.2019*

*Abgeschlossen*

**BASE: An open label, randomized study to compare the efficacy of Certolizumab pegol (CZP) plus a dynamic or fixed dose treatment strategy in patients with Rheumatoid Arthritis, a phase II study**

*Klinische Forschung - 07.11.2013 - 03.07.2023*

*Abgeschlossen*

**Arthritis check up: Evaluation einer Strategie zur Früherkennung der Rheumatoider Arthritis**

*Grundlagenforschung - 16.09.2009 - 30.11.2024*

*Laufend*

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch